Hygromycin B

DB11520

small molecule vet_approved

Deskripsi

Hygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.

Struktur Molekul 2D

Berat 527.524
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

868 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Hygromycin B.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Hygromycin B.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Hygromycin B.
Cisatracurium Hygromycin B may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Hygromycin B.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Hygromycin B.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Hygromycin B.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Hygromycin B.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Hygromycin B.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Hygromycin B.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Hygromycin B.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Hygromycin B.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Hygromycin B.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Hygromycin B.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Hygromycin B.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Hygromycin B.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Hygromycin B.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Hygromycin B.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Hygromycin B.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Hygromycin B.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Hygromycin B is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Hygromycin B is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Hygromycin B.
Tenofovir disoproxil Hygromycin B may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Hygromycin B may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Hygromycin B may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Hygromycin B.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Incadronic acid.
Pamidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Pamidronic acid.
Tiludronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Tiludronic acid.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Hygromycin B.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Hygromycin B.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Hygromycin B.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Hygromycin B.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Hygromycin B.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Hygromycin B.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Hygromycin B.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Hygromycin B.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Hygromycin B.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Hygromycin B.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Hygromycin B.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Hygromycin B.
Framycetin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Hygromycin B.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Hygromycin B.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Hygromycin B.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Hygromycin B.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Hygromycin B.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Hygromycin B.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Hygromycin B.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Hygromycin B.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Hygromycin B.
Piroxicam The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Hygromycin B.
Methotrexate The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Hygromycin B.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Hygromycin B.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Hygromycin B.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Hygromycin B.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Hygromycin B.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Hygromycin B.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Hygromycin B.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Hygromycin B.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Hygromycin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Hygromycin B.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Hygromycin B.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Hygromycin B.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Hygromycin B.
Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Hygromycin B.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Hygromycin B.
Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Hygromycin B.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Hygromycin B.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Hygromycin B.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Hygromycin B.
Meloxicam The risk or severity of methemoglobinemia can be increased when Hygromycin B is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Hygromycin B.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Hygromycin B.
Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Hygromycin B.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Hygromycin B.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Hygromycin B.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Hygromycin B.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Hygromycin B.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Hygromycin B.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Hygromycin B.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Hygromycin B.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Hygromycin B.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Hygromycin B.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Hygromycin B.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Hygromycin B.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Hygromycin B.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Hygromycin B.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Hygromycin B.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Hygromycin B.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Hygromycin B.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Hygromycin B.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Hygromycin B.
Olsalazine The risk or severity of nephrotoxicity can be increased when Hygromycin B is combined with Olsalazine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2818375
    Watson AD, Burnett DC: Hygromycin B and deaf dogs. Aust Vet J. 1989 Sep;66(9):302-3.
  • PMID: 5298042
    Davidson I, Hebert CN: The international reference preparation of hygromycin B. Bull World Health Organ. 1966;35(6):933-43.
  • PMID: 5493473
    Tsyganov VA, Pronina MI: Selection of strains producing hygromycin B using roentgen rays. Antibiotiki. 1970 Aug;15(8):679-82.
  • PMID: 4592490
    Begue WJ, Kline RM: Semiquantitative microbiological residue method for hygromycin B in chicken eggs. J Assoc Off Anal Chem. 1973 Jan;56(1):20-2.
  • PMID: 24130756
    Radman I, Greiss S, Chin JW: Efficient and rapid C. elegans transgenesis by bombardment and hygromycin B selection. PLoS One. 2013 Oct 9;8(10):e76019. doi: 10.1371/journal.pone.0076019. eCollection 2013.
  • PMID: 14405258
    KELLEY GW, OLSEN LS: Critical tests of hygromycin B as an ascaricide of swine. Cornell Vet. 1960 Jan;50:60-5.
  • PMID: 2759709
    Gonzalez R, Ferrer S, Buesa J, Ramon D: Transformation of the dermatophyte Trichophyton mentagrophytes to hygromycin B resistance. Infect Immun. 1989 Sep;57(9):2923-5.
  • PMID: 12820169
    Makridou P, Burnett C, Landy T, Howard K: Hygromycin B-selected cell lines from GAL4-regulated pUAST constructs. Genesis. 2003 Jun;36(2):83-7.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul